MP
LRMR icon

Mangrove Partners’s Larimar Therapeutics LRMR Stock Holding History

Mangrove Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-442,236
Closed -$1.43M – 413
2025
Q3 		$1.43M Sell
442,236
-327,997
-43% -$1.23M 0.11% 87
2025
Q2 		$2.23M Hold
770,233
– – 0.24% 52
2025
Q1 		$1.66M Hold
770,233
– – 0.18% 63
2024
Q4 		$2.98M Sell
770,233
-85,582
-10% -$565K 0.33% 50
2024
Q3 		$5.61M Hold
855,815
– – 0.48% 56
2024
Q2 		$6.2M Hold
855,815
– – 0.48% 61
2024
Q1 		$6.5M Buy
855,815
+50,000
+6% +$390K 0.45% 65
2023
Q4 		$3.67M Hold
805,815
– – 0.25% 93
2023
Q3 		$3.18M Hold
805,815
– – 0.24% 105
2023
Q2 		$2.52M Hold
805,815
– – 0.17% 133
2023
Q1 		$3.65M Sell
805,815
-486,997
-38% -$2.54M 0.24% 136
2022
Q4 		$5.34M Hold
1,292,812
– – 0.3% 85
2022
Q3 		$4.14M Buy
1,292,812
+425,000
+49% +$1.06M 0.24% 174
2022
Q2 		$1.7M Hold
867,812
– – 0.08% 341
2022
Q1 		$3.52M Buy
867,812
+627,859
+262% +$4.11M 0.19% 207
2021
Q4 		$2.59M Buy
+239,953
New +$2.67M 0.15% 210
2020
Q4 		– Sell
-146,142
Closed -$2.22M – 113
2020
Q3 		$2.22M Hold
146,142
– – 0.28% 45
2020
Q2 		$1.88M Sell
146,142
-760
-0.5% -$8.85K 0.46% 36
2020
Q1 		$1.36M Sell
146,902
-1,152
-0.8% -$15.1K 0.19% 41
2019
Q4 		$1.97M Hold
148,054
– – 0.29% 37
2019
Q3 		$1.31M Hold
148,054
– – 0.16% 68
2019
Q2 		$2.11M Buy
148,054
+47,277
+47% +$1.26M 0.24% 53
2019
Q1 		$3.31M Buy
100,777
+39,308
+64% +$2.01M 0.44% 41
2018
Q4 		$3.65M Hold
61,469
– – 0.49% 37
2018
Q3 		$8.62M Hold
61,469
– – 0.54% 21
2018
Q2 		$7.55M Buy
61,469
+12,500
+26% +$1.06M 0.49% 21
2018
Q1 		$4.38M Hold
48,969
– – 0.29% 28
2017
Q4 		$2.71M Buy
48,969
+2,304
+5% +$104K 0.37% 27
2017
Q3 		$1.97M Buy
+46,665
New +$1.94M 0.34% 28

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mangrove Partners's LRMR Position: Q4 2025 in Review

Mangrove Partners sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 442,236 shares — an estimated $1.43M sold.

Mangrove Partners first reported a position in LRMR in Q3 2017 and held it in 29 quarters. The position peaked at $8.62M in Q3 2018. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

  • Mangrove Partners reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mangrove Partners sold 442,236 Larimar Therapeutics shares in Q4 2025, an estimated $1.43M.
  • Mangrove Partners first reported a position in Larimar Therapeutics in Q3 2017 and held it in 29 quarters.
  • Mangrove Partners's Larimar Therapeutics position peaked at $8.62M in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Mangrove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.